Skip to main content
SpringerLink
Log in

TNF–α converting enzyme (TACE) protein expression in different clinical subtypes of multiple sclerosis

  • ORIGINAL COMMUNICATION
  • Published:
Journal of Neurology Aims and scope Submit manuscript

Abstract

Tumor necrosis factor (TNF)–α converting enzyme (TACE, also called ADAM17) is a key sheddase that releases TNF–α from its inactive cell–bound precursor. TACE protein expression levels in peripheral blood mononuclear cells were measured by Western blot analysis in 20 healthy controls and 80 multiple sclerosis (MS) patients before and after treatment with IFNβ [20 patients with primary progressive (PP) MS, 20 patients with secondary progressive (SP) MS, and 40 patients with relapsing– remitting (RR) MS (20 patients during clinical remission and 20 patients in relapse)]. TNF–α serum levels were also measured by enzyme–linked immunoassay in the MS patients and healthy controls. TACE protein expression levels were lower in healthy controls and PPMS patients compared with SPMS patients and RRMS patient during clinical remission. No differences in TACE protein levels were observed between RRMS patients in relapse and during remission. TACE protein levels were increased in PPMS patients treated with IFNβ. Serum TNF–α levels were higher in RRMS patients in relapse compared with RRMS patients during remission, and positive and negative correlations were found between TACE protein expression and serum TNF–α levels in RRMS patients during relapse and during remission respectively. These findings point to different regulatory mechanisms of the TACE–TNF–α pathway in the clinical MS subtypes and expand the role of TACE in MS pathogenesis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Compston A, Coles A (2002) Multiple sclerosis. Lancet 359:1221–1231

    Article  PubMed  Google Scholar 

  2. Leppert D, Ford J, Stabler G,Grygar C, Lienert C, Huber S, Miller KM, Hauser SL, Kappos L (1998) Matrix metalloproteinase-9 (gelatinase B) is selectively elevated in CSF during relapses and stable phases of multiple sclerosis. Brain 121:2327–2334

    Article  PubMed  Google Scholar 

  3. Galboiz Y, Shapiro S, Lahat N, Rawashdeh H, Miller A (2001) Matrix metalloproteinases and their tissue inhibitors as markers of disease subtype and response to interferon-beta therapy in relapsing and secondary progressive multiple sclerosis patients. Ann Neurol 50:443–551

    Article  PubMed  CAS  Google Scholar 

  4. Avolio C, Ruggieri M, Giuliani F, Liuzzi GM, Leante R, Riccio P, Livrea P, Trojano M (2003) Serum MMP-2 and MMP-9 are elevated in different multiple sclerosis subtypes. J Neuroimmunol 136:46–53

    Article  PubMed  CAS  Google Scholar 

  5. Black RA (2002) Tumor necrosis factor-alpha converting enzyme. Int J Biochem Cell Biol 34:1–5

    Article  PubMed  CAS  Google Scholar 

  6. Moro MA, Hurtado O, Cardenas A, Romera C, Madrigal JLM, Fernandez-Tome P, Leza JC, Lorenzo P, Lizasoain I (2003) Expression and function of TACE (TNF-alpha converting enzyme) in the central nervous system. Neurosignals 12:53–58

    Article  PubMed  CAS  Google Scholar 

  7. Peschon JJ, Slack JL, Reddy P, Stocking KL, Sunnarborg SW, Lee DC, Russell WE, Castner BJ, Johnson RS, Fitzner JN, Boyce RW, Nelson N, Kozlosky CJ, Wolfson MF, Rauch CT, Cerretti DP, Paxton RJ, March CJ, Black RA (1998) An essential role for ectodomain shedding in mammalian development. Science 282:1281–1284

    Article  PubMed  CAS  Google Scholar 

  8. Reddy P, Slack JL, Davis R, Cerretti DP, Kozlosky CJ, Blanton RA, Shows D, Peschon JJ, Black RA (2000) Functional analysis of the domain structure of tumor necrosis factor-alpha converting enzyme. J Biol Chem 275:14608–14614

    Article  PubMed  CAS  Google Scholar 

  9. Althoff K, Reddy P, Voltz N, Rose-John S, Mullberg J (2000) Shedding of interleukin- 6 receptor and tumor necrosis factor alpha. Contribution of the stalk sequence to the cleavage pattern of transmembrane proteins. Eur J Biochem 267:2624–2631

    Article  PubMed  CAS  Google Scholar 

  10. Budagian V, Bulanova E, Orinska Z, Ludwig A, Rose-John S, Saftig P, Borden EC, Bulfone-Paus S (2004) Natural soluble interleukin-15Ralpha is generated by cleavage that involves the tumor necrosis factor-alpha-converting enzyme (TACE/ADAM17). J Biol Chem 279:40368–40375

    Article  PubMed  CAS  Google Scholar 

  11. Garton KJ, Gough PJ, Blobel CP, Murphy G, Greaves DR, Dempsey PJ, Raines EW (2001) Tumor necrosis factor-alpha-converting enzyme (ADAM17) mediates the cleavage and shedding of fractalkine (CX3CL1). J Biol Chem 276:37993–38001

    PubMed  CAS  Google Scholar 

  12. Condon TP, Flournoy S, Sawyer GJ, Baker BF, Kishimoto TK, Bennett CF (2001) ADAM17 but not ADAM10 mediates tumor necrosis factor-alpha and L-selectin shedding from leukocyte membranes. Antisense Nucleic Acid Drug Dev 11:107–116

    Article  PubMed  CAS  Google Scholar 

  13. Garton KJ, Gough PJ, Philalay J, Wille PT, Blobel CP, Whitehead RH, Dempsey PJ, Raines EW (2003) Stimulated shedding of vascular cell adhesion molecule 1 (VCAM-1) is mediated by tumor necrosis factor-alpha-converting enzyme (ADAM 17). J Biol Chem 278:37459–37464

    Article  PubMed  CAS  Google Scholar 

  14. Sharief MK, Hentges R (1991) Association between tumor necrosis factoralpha and disease progression in patients with multiple sclerosis. N Engl J Med 325:467–472

    Article  PubMed  CAS  Google Scholar 

  15. Bertolotto A, Malucchi S, Capobianco M, Manzardo E, Guastamacchia G, Milano E, Audano L, Mutani R (1999) Quantitative PCR reveals increased levels of tumor necrosis factor-alpha mRNA in peripheral blood mononuclear cells of multiple sclerosis patients during relapses. J Interferon Cytokine Res 19:575–581

    Article  PubMed  CAS  Google Scholar 

  16. Seifert T, Kieseier BC, Ropele S, Strasser-Fuchs S, Quehenberger F, Fazekas F, Hartung HP (2002) TACE mRNA expression in peripheral mononudear cells precedes new lesions on MRI in multiple sclerosis. Mult Scler 8:447–451

    Article  PubMed  CAS  Google Scholar 

  17. Kieseier BC, Pischel H, Neuen-Jacob E, Tourtellotte WW, Hartung HP (2003) ADAM-10 and ADAM-17 in the inflamed human CNS. Glia 42:398–405

    Article  PubMed  Google Scholar 

  18. Lublin FD, Reingold SC (1996) Defining the clinical course of multiple sclerosis: results of an international survey. Neurology 46:907–911

    PubMed  CAS  Google Scholar 

  19. Montalban X (2004) Overview of European pilot study of interferon β- 1b in primary progressive multiple sclerosis. Mult Scler 10:S62–S64

    Article  PubMed  Google Scholar 

  20. Hurtado O, Lizasoain I, Fernandez-Tome P, Moro MA, Alvarez-Barrientos A, Leza JC, Lorenzo P, et al. (2002) TACE/ADAM17-TNF-a pathway in rat cortical cultures after exposure to oxygen-glucose-deprivation or glutamate. J Cereb Blood Flow Metabolism 22:576–585

    Article  CAS  Google Scholar 

  21. Schlöndorff J, Becherer JD, Blobel CP (2000) Intracellular maturation and localization of the tumour necrosis factor a convertase (TACE). Biochem J 347:131–138

    Article  PubMed  Google Scholar 

  22. Thompson AJ, Polman CH, Miller DH, McDonald WI, Brochet B, Filippi M, Montalban X, De Sa J (1997) Primary progressive multiple sclerosis. Brain 120:1085–1096

    Article  PubMed  Google Scholar 

  23. Revesz T, Kidd D, Thompson AJ, Barnard RO, McDonald WI (1994) A comparison of the pathology of primary and secondary progressive multiple sclerosis. Brain 117:759–765

    PubMed  Google Scholar 

  24. Giovannoni G, Lai M, Thorpe J, Kidd D, Chamoun V, Thompson AJ, Miller DH, Feldmann M, Thompson EJ (1997) Longitudinal study of soluble adhesion molecules in multiple sclerosis: correlation with gadolinium enhanced magnetic resonance imaging. Neurology 48:1557–1565

    PubMed  CAS  Google Scholar 

  25. Duran I, Martinez-Caceres EM, Rio J, Barbera N, Marzo ME, Montalban X (1999) Immunological profile of patients with primary progressive multiple sclerosis. Expression of adhesion molecules. Brain 122:2297–2307

    Article  PubMed  Google Scholar 

  26. Sastre-Garriga J, Comabella M, Brieva L, Rovira A, Tintore M,Montalban X (2004) Decreased MMP-9 production in primary progressive multiple sclerosis patients. Mult Scler 10:376–380

    Article  PubMed  CAS  Google Scholar 

  27. Vladic A, Horvat G, Vukadin S, Sucic Z, Simaga S (2002) Cerebrospinal fluid and serum protein levels of tumour necrosis factor-alpha (TNF-alpha) interleukin-6 (IL-6) and soluble interleukin-6 receptor (sIL-6R gp80) in multiple sclerosis patients. Cytokine 20:86–89

    Article  PubMed  CAS  Google Scholar 

  28. Rovaris M, Barnes D, Woodrofe N, du Boulay GH, Thorpe JW, Thompson AJ, McDonald WI, Miller DH (1996) Patterns of disease activity in multiple sclerosis patients: a study with quantitative gadolinium-enhanced brain MRI and cytokine measurement in different clinical subgroups. J Neurol 243:536–542

    Article  PubMed  CAS  Google Scholar 

  29. Vikas V, Link H (1996) Review: cytokines and the pathogenesis of multiple sclerosis. J Neurosci Res 45:322–333

    Article  Google Scholar 

  30. Hollifield RD, Harbige LS, Pham-Dinh D, Sharief MK (2003) Evidence for cytokine dysregulation in multiple sclerosis: peripheral blood mononuclear cell production of pro-inflammatory and anti-inflammatory cytokines during relapse and remission. Autoimmunity 36:133–141

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Unitat de Neuroimmunologia Clínica, Hospital Universitari Vall d’Hebron, Escuela de Enfermeria 2a planta, Psg Vall d’Hebron 119-129, 08035, Barcelona, Spain

    M. Comabella MD, M. Camiña, H. Perkal, M. Castillo & X. Montalban

  2. Departamento de Farmacología, Facultad de Medicina, Universidad Complutense de Madrid, Spain

    C. Romera, M. A. Moro, J. C. Leza & I. Lizasoain

Authors
  1. M. Comabella MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. C. Romera
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M. Camiña
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. H. Perkal
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M. A. Moro
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. J. C. Leza
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. I. Lizasoain
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. M. Castillo
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. X. Montalban
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M. Comabella MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Comabella, M., Romera, C., Camiña, M. et al. TNF–α converting enzyme (TACE) protein expression in different clinical subtypes of multiple sclerosis. J Neurol 253, 701–706 (2006). https://doi.org/10.1007/s00415-006-0090-6

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00415-006-0090-6

Key words

Search

Navigation